Recent studies suggest that bevacizumab, by targeting vascular endothelial growth factor (VEGF) within the brain without requiring BBB penetration, may represent an effective therapeutic strategy for CRC-related BM (221, 222). This evidence concerns the gene VEGFA and colorectal carcinoma.